|
Artemisinin, Malaria,
and Cancer
by CJ Puotinen
Updated Information from
NEHA Journal Winter, 2003 Issue
Herbs have always played an
important role in alternative cancer therapies, but no
matter how effective they may be, conventional Western
medicine ignores them.
That attitude may soon change, for the latest herb to be
recognized for its cancer-fighting properties was
discovered not by alternative practitioners but by
medical researchers working at a respected university.
The
herb is sweet Annie (Artemisia annua), also known
in the West as sweet wormwood or annual wormwood and in
China as Qinghao. Its cousin is the more familiar
perennial wormwood, Artemisia absinthium.
The discovery's story began during the Vietnam War, when
the North Vietnamese army constructed an elaborate
network of underground tunnels. As the tunnels collected
rainwater, mosquitoes that carried malaria reproduced in
their standing water. The problem grew so severe that
North Vietnam lost more soldiers to malaria than to
military weapons.
Ho Chi Min, North Vietnam's leader, turned to China for
help, and Chairman Mao Tse-tung assured him that China's
scientists could develop a new malaria cure. Researchers
at the Chinese Institute of Material Medicine found a
region of China that reported no malaria cases, and when
they investigated, they discovered that its people drank
a decoction (simmered tea) of Artemesia annua at the
first sign of malarial symptoms.
In 1972, the scientists
isolated four chemical compounds in the plant:
artesunate, artemether, arteether, and artemisinin.
Three have medicinal applications.
Artesunate, which is a water-soluble synthetic compound,
is the most active and least toxic of the four, but it
breaks down rapidly in the body.
Artemether, another synthetic compound, is fat-soluble,
breaks down slowly, and is the most toxic of the four
when taken in high doses. Its therapeutic dose is far
below the danger level. Artemether's main advantage is
that it can cross the blood-brain barrier.
Artemisinin, which occurs naturally in sweet wormwood,
is the least expensive compound to produce, and it's
considered the safest and most effective. It, too,
crosses the blood-brain barrier. Some practitioners use
artemisinin alone, while others prefer combinations of
artemisinin and artesunate and/or artemether.
Artemisinin became the drug of choice for malaria. It
has since become popular throughout Southeast Asia and
Africa, where malaria has become resistant to nearly all
anti-malarial drugs, including chloroquine, quinine,
mefloquine, and Fansidar. Malaria infects an estimated
270 million people worldwide, with about 80 percent of
cases occurring in Africa. So far, malaria has not
developed resistance to artemisinin.
In 1993, a University of Michigan researcher discovered
the biochemical mechanism that makes artemisinin work.
Dr. Steven R. Meshnick, a parasitologist at the
University's School of Public Health, found that the
malaria parasite survives in its host by consuming
approximately 25 percent of the hemoglobin in the host's
red blood cells. However, it does not metabolize the
heme (iron) in the hemoglobin. Instead, it stores the
iron in the form of a polymer called hemozoin, inside a
food vacuole.
"We discovered that when artemisinin comes into contact
with the iron in the hemozoin," he said, "the iron
converts the drug into a toxic chemical, releasing a
free radical that destroys the parasite." In Dr.
Meshnick's clinical study of 638 malarial patients in
Vietnam, artemisinin eliminated 98 percent of malarial
parasites within 24 hours and did so without significant
side effects. "The parasite reappeared in only 10 to 23
percent of the group that took artemisinin for five to
ten days," he said. "It may well be that the
re-appearance of the disease was due to a new infection
rather than a flare-up of the prior one." Artemisinin
was equally effective against both the falciparum and
vivax strains of malaria.
Artemisinin's reaction to iron molecules interested
Research Professors Henry Lai, Ph.D., and Narendra
Singh, M.B.B.S., at the University of Washington in
Seattle because cancer cells, like malaria parasites,
collect and store iron. "Cancer cells need extra iron to
replicate DNA when they divide," explains Professor Lai.
"As a result, cancer cells have a much higher
concentration of iron than normal cells do. When we
began to understand how artemisinin works, I wondered if
we could use that knowledge to target cancer cells."
In research published in 1995 in the journal Cancer
Letters and in the November 2001 journal Life Sciences,
Professors Lai and Singh found that artemisinin killed
all of the human leukemia and breast cancer cells in a
test tube within 8 to16 hours while leaving nearly all
of the normal cells unharmed.
Artemisinin has been shown in test tube studies to be
most effective against leukemia and colon cancer, while
preliminary tests suggest that artemisinin will be
effective against melanoma, breast, ovarian, prostate,
renal, and central nervous system cancers such as
glioblastoma and neuroblastoma.
In 1999, Professors Lai and Singh pioneered canine
research on artemisinin when, in collaboration with
Tejinder Sodhi, DVM, of the Animal Hospital of Lynnwood
in Lynnwood, Washington, they treated a male Golden
Retriever whose bone tumor caused acute lameness.
Despite a very low dose and short treatment time (artemisinin
was then expensive and the project lacked funding to buy
more), the dog recovered after 10 days of treatment,
gaining weight and walking normally, with x-rays showing
signs of bone remodeling. In another case, a 7-year-old
male Basset Hound was diagnosed with lymphosarcoma of
the lymph nodes. After three 5-day treatments separated
by intervals of three to five days, the diameter of
inguinal and submandibular, right and left, lymph nodes
were reduced to half. Both dogs recovered without
further treatment.
As this article goes to press (April 2003), the
Washington Cancer Institute Department of Orthopedic
Oncology, Georgetown University Medical Center, and a
fellowship-trained veterinary surgical oncologist in
Washington, DC, are collaborating on a project to
determine whether artemisinin is an effective compound
in the treatment of canine osteosarcoma. "We are
performing in vitro or laboratory assays, the results of
which will be determined by June 2003," says Senior
Clinical Researcher Kristen Kellar-Graney at the
Washington Cancer Institute. "If these results prove
favorable, it is our intention to perform a small,
double-blinded, randomized study with pet canines who
are not eligible for other forms of conventional
treatment or pets whose owners are not interested in or
cannot afford more conventional methods of treatment."
Sweet Annie grows around the world, but not every plant
contains artemisinin. The most productive plants have
been found on plantations in North Vietnam near Hanoi
and in the wild on steep hills in China's Chongqing
province, especially at altitudes above 1000 meters
(3000 feet). Holley Pharmaceuticals imports high-quality
artemisinin from China. According to Holley USA's
president Michael Liu, the leaves of Artemisia annua are
harvested just before budding, sun-dried for a day, then
transported in specially designed trucks to a nearby
factory. "They are first extracted by a fat solvent," he
explains, "then the base liquid is separated. A second
extraction is done with an organic solvent, then the
extract is concentrated and crystallized, producing
crude artemisinin. The dissolution, filtration,
concentration, and recrystallization steps are repeated
several times until the result is pure artemisinin,
which is tested by high performance liquid
chromatography (HPLC) for purity and tested against
cancer cell lines for bio-assay."
The recommended human dose is approximately 1 milligram
(mg) of artemisinin per kilogram (2.2 pounds) of body
weight twice per day. For a 100-lb person, this would be
45 mg twice a day, and for someone weighing 180 lbs, it
would be 82 mg twice a day. Because artemisinin is sold
in 50-mg and 100-mg capsules, these doses are usually
rounded up to the closest available dose. According to
the researchers interviewed here, artemisinin should be
taken for at least one month and can be taken for up to
six to twelve months at a time.
Vitamin C, coenzyme Q10, pancreatic enzymes, medicinal
herbs, and other supplements used in holistic cancer
therapies are compatible with artemisinin, although some
practitioners recommend separating artemisinin and high
doses of vitamin C by at least three hours.
Some practitioners recommend giving cod liver oil or
other fat with artemisinin to improve its assimilation,
but Professor Lai reports that this is not necessary.
Artemisinin should not be combined with radiation
therapy because radiation treatments release iron stored
in cancer cells to surrounding tissue. For best results,
patients are encouraged to wait until at least two
months after their last radiation treatment before
beginning artemisinin.
However, artemisinin is compatible with chemotherapy. In
a study published in 2002, German researcher T. Efferth,
Ph.D., tested artemisinin in combination with 22
chemotherapy drugs and found that artemisinin enhanced
the drugs' effectiveness. When artemisinin is used in
combination with chemotherapy, it should be taken
several hours after the chemotherapy treatment ends.
When taken in combination with chemotherapy, artemisinin
does not alleviate chemotherapy's side effects.
In the May 2002 issue of his Second Opinion newsletter
(PO Box 467939, Atlanta GA 31146-7939, phone
1-800-728-2288 or 770-399-5617), Robert J. Rowen, MD,
reported on several cases in which he and other
physicians used artemisinin with excellent results. Dr.
Rowen reprinted these in his booklet "New Breakthroughs
for Preventing and Surviving Cancer," available from the
same publisher. In one case, he treated a 47-year-old
mechanic with a tumor on his head just after the man's
oncologist diagnosed lymphoma. Dr. Rowen immediately
prescribed artemisinin, which the patient took for two
weeks. At the end of that time, the lump developed a
small depression in its center, but the perimeter had
grown slightly. The patient felt discouraged and decided
not to continue taking artemisinin. He received no other
medical treatment. Four weeks later, his tumor
disappeared.
Dr. Rowen has also interviewed Vietnamese physicians
have used artemisinin for ten years. They report a
long-term remission success rate of 50 to 60 percent in
400 cancer patients treated with artemisinin combined
with a comprehensive integrative cancer strategy. See
Dr. Rowen's publications for further information.
In addition to curing malaria and some cancers,
artemisinin may have other applications.
Like several members of the Artemisia family, sweet
wormwood has been used in herbal products that treat
internal parasites. Although this use is experimental,
some practitioners recommend artemisinin as an
anti-parasite therapy.
While all agree that cancer is best treated in its
earliest stages, no one has formally tested artemisinin
as a cancer preventive or determined whether it is safe
for use by those who don't have cancer or who might or
might not have undiagnosed, early-stage cancer. Some
health care practitioners are experimenting with
one-month courses of artemisinin for themselves or their
pets. Also, some physicians have reported good results
from treating Lyme disease with artemisinin. These are
experimental or untested applications of the product. No
doubt they will be explored by researchers in the
future.
As exciting and convenient as this new product is, some
herbalists prefer to use the whole herb or whole-herb
extracts rather than the "silver bullet" of refined
artemisinin. One is botanist James A. Duke, Ph.D.,
prolific author, researcher, expert on the medicinal
benefits of herbs and, until his retirement, affiliated
with the U.S. Department of Agriculture.
"Sweet Annie contains half a dozen or more antiviral
compounds," he explains, "some of which are proven
synergic. One naturopathic physician, Dr. S. Morris, was
on ecotour in NgoraNgora Crater, where all mosquitoes
are malarial. He took a tincture of Artemisia annua
instead of chloroquine or larium, which the rest of us
were taking for malaria prevention. None of us go
malaria. Subsequently, that's what I have taken as a
preventive in Amazonian Peru, where even my shaman
caught malaria."
According to Dr. Duke, some research has shown that the
whole herb is more active than artemisinin, that gelatin
capsules of the herb are 3.5 times more effective than
artemisinin for clearing parasitemia in mice. "The
whole-herb capsules are better than chloroquine for
fever and malarial symptoms," he says. "When it comes to
malaria, I personally believe that whole extracts of
Artemisia annua, with all their synergens, could be
better and cheaper than the isolated silver bullet, or
derivatives thereof, at preventing as well as treating
malaria. It could have fewer side effects and would be
less likely to lead to multidrug resistance.
"But when it comes to cancer, there are few cut and
dried answers. I would myself experiment with tinctures,
cold-water infusions, and hot teas of Artemisia annua
for a recalcitrant cancer. This is not a recommendation
for anyone, it's just my personal opinion. Perhaps the
answer will be found by testing whole-herb cold-water
extracts in human beings."
Product Sources:
Holley Pharmaceuticals artemether (40-mg softgels and
tablets), artesunate (50-mg capsules), and other
products derived from artemisinin are available only to
healthcare professionals, research scientists, or
customers living outside the United States. For
information on these products, contact manager@holleypharma.com.
Allergy Research Group in Hayward, CA (phone
1-800-545-9960, www.allergyresearchgroup.com) offers
three supplements derived from Sweet Annie that are sold
in health food stores. Artemisia capsules contain 500 mg
powdered Artemisia annua (120 capsules, $27, retail
price); Artemisia Forte II capsules contain 150 mg
Artemisia annua, 10 mg artemisinin, and 125 mg citrus
seed extract (90 capsules, $40); and artemisinin
capsules contain 100 mg artemisinin (90 capsules, $24).
Information:
For information regarding cancer research and treatment
using artemisinin, contact Professor Henry Lai, Ph.D.,
University of Washington, Seattle. Phone 206-543-1071,
email
hlai@u.washington.edu.
For information regarding canine cancer research using
artemisinin, contact Kristen Kellar-Graney, Washington
Cancer Institute, Washington, DC. Phone 202-877-3390,
www.sarcoma.org, email kporkchop@hotmail.com.
|